Related Experiment Video
Updated: Jul 8, 2026

A High-performance Liquid Chromatography Measurement of Kynurenine and Kynurenic Acid: Relating Biochemistry to Cognition and Sleep in Rats
Published on: August 19, 2018
Exploring the Microbiome-Kynurenine Axis in Mild Cognitive Impairment: From Gut to Brain
Jiaxing Zhu1, Haihua Xie1, Yingke Ouyang1
1College of Acupuncture & Tuina and Rehabilitation, Hunan University of Chinese Medicine, 410208 Changsha, Hunan, China.
Abstract:
Mild cognitive impairment (MCI) represents a critical prodromal stage of Alzheimer's disease. This review synthesizes current evidence to present a coherent pathological cascade driving MCI progression: gut microbiota dysbiosis (e.g., enrichment of Prevotella and depletion of Akkermansia) triggers a butyrate deficit and compromise of intestinal integrity, leading to systemic inflammation. This inflammatory milieu upregulates indoleamine 2,3-dioxygenase 1 (IDO1), shifting tryptophan metabolism toward the kynurenine pathway and resulting in the dominance of neurotoxic branches (3-hydroxykynurenine [3-HK], quinolinic acid [QUIN]) over neuroprotective kynurenic acid (KYNA). This metabolic imbalance promotes N-methyl-D-aspartate (NMDA) receptor-mediated excitotoxicity, oxidative stress, and neuroinflammation, which collectively precipitate synaptic dysfunction and cognitive decline. We explicitly highlight this "gut-immune-metabolic" vicious cycle as the core framework of MCI pathology. Targeting this cycle through a dual strategy-restoring microbial diversity and pharmacologically inhibiting the IDO1/kynurenine 3-monooxygenase (KMO) enzymes-represents a promising therapeutic approach to delay the transition from MCI to dementia.
Insights
Gut microbiota changes trigger inflammation and alter brain metabolism, driving mild cognitive impairment (MCI) progression. Targeting this gut-immune-metabolic cycle may delay dementia.
Area of Science:
- Neuroscience
- Microbiology
- Immunology
Background:
- Mild cognitive impairment (MCI) is a precursor to Alzheimer's disease.
- Gut microbiota dysbiosis is implicated in various neurological disorders.
Purpose of the Study:
- To review the pathological cascade linking gut dysbiosis to MCI.
- To propose therapeutic targets within the gut-immune-metabolic axis.
Main Methods:
- Literature review synthesizing evidence on MCI pathogenesis.
- Analysis of the role of gut microbiota, inflammation, and tryptophan metabolism.
Main Results:
- Gut dysbiosis (e.g., altered Prevotella and Akkermansia) leads to butyrate deficit and compromised gut integrity.
- Systemic inflammation upregulates IDO1, favoring neurotoxic kynurenine pathway metabolites.
- This imbalance promotes excitotoxicity, oxidative stress, and neuroinflammation, causing cognitive decline.
Conclusions:
- A 'gut-immune-metabolic' vicious cycle drives MCI progression.
- Dual therapeutic strategies targeting microbial restoration and IDO1/KMO inhibition show promise for delaying dementia.
Related Concept Videos
Gut-Brain Axis
Dysbiosis of the Gut Microbiota
Functions of the Gut Microbiota
Alzheimer Disease ll: Pathophysiology
Microbiota Modulation by Antibiotics
Alzheimer Disease l: Introduction
